#None #Target RWE #Liver Disease #Amsterdam #EASL 2025

Target RWE Shines at EASL 2025 Congress

In the vibrant atmosphere of the EASL Congress 2025, held in Amsterdam, Target RWE emerged as a key player, showcasing groundbreaking research and insights that are set to reshape the understanding of liver diseases. This annual international congress attracts the foremost experts and stakeholders interested in advancing liver health, and Target RWE's presentations on metabolic dysfunction-associated steatohepatitis (MASH), hepatocellular carcinoma (HCC), and primary biliary cholangitis (PBC) captured significant attention.

Advancing Research with Real-World Evidence

Target RWE specializes in harnessing real-world data to provide robust insights into complex diseases. As the regulatory landscape becomes increasingly stringent, there is a growing need for comprehensive evidence to support treatment strategies. At EASL 2025, Target RWE demonstrated how their innovative methodologies can aid biopharma companies in making informed decisions regarding patient screening and treatment options. They emphasized the importance of:

1. Identifying MASH patients without invasive biopsies. This approach reduces the risk for patients while allowing clinical trials to recruit more effectively.
2. Assessing therapy patterns in PBC. Understanding the long-term efficacy for patients unresponsive to first-line treatments is crucial for developing alternative strategies.
3. Evaluating comorbidities' impacts. Recognizing how other health issues affect MASH treatment can lead to personalized and more effective care plans.
4. Integrating patient perspectives. By focusing on quality of life and treatment satisfaction, researchers can align therapies with patient needs, ultimately improving adherence and outcomes.

By addressing these aspects, Target RWE not only bridges evidence gaps but also mitigates regulatory risks, accelerating the development of therapies for liver diseases.

Leadership at the PBC Consensus Conference

Another highlight of EASL 2025 was the participation of Dr. Michael W. Fried, Co-Founder and Chief Medical Officer of Target RWE, in the PBC Consensus Conference. This pre-congress event focused on establishing reliable surrogate endpoints and the value of real-world evidence in clinical trial designs specific to PBC, an area where treatment strategies are still evolving.

Dr. Fried, an influential figure in hepatology, remarked, “This conference provides a vital platform to harmonize our research methodologies and ensure that clinical trials reflect the real-world experiences of patients.” The outcomes of this consensus will be paramount in refining therapeutic approaches and enhancing patient outcomes in PBC research.

Unveiling New Insights: HCC and MASH

During the congress, Target RWE presented compelling findings from its research on MASH and HCC:

• - In a pivotal study presented at EASL, researchers found that individuals with type 2 diabetes have a higher risk of developing cirrhosis related to metabolic dysfunction-associated steatohepatitis. This surprising correlation emphasizes the urgent need for targeted screening in diabetic populations.
• - The second abstract provided a thorough analysis of treatment patterns for HCC patients undergoing procedures like transarterial chemoembolization (TACE) and transarterial radioembolization (TARE). The findings revealed significant disparities in treatment approaches, with many patients deemed unsuitable for recommended courses of therapy.

Both studies highlight the pressing need for refined strategies in diagnosing and managing liver diseases. They illustrate how Target RWE’s data-driven insights can inform current practices and lead to better patient outcomes, especially in the nuanced fields of liver disease management.

The Future of Liver Disease Research

As the congress concluded, it became evident that Target RWE is firmly positioned at the forefront of liver disease research. By continuing to leverage real-world evidence and foster collaboration among experts, the company is paving the way for a future where treatment development aligns closely with real patient experiences. With continued innovation and emphasis on patient-centered research, the journey toward improving liver disease therapies is indeed on a promising path.

For more information about Target RWE and their ongoing contributions to liver disease research, visit Target RWE's website or contact them directly.